Literature DB >> 18810397

Starting insomnia treatment: the use of benzodiazepines versus z-hypnotics. A prescription database study of predictors.

Anne M Hausken1, Kari Furu, Svetlana Skurtveit, Anders Engeland, Jørgen G Bramness.   

Abstract

PURPOSE: Drugs prescribed for the treatment of insomnia can be either benzodiazepine hypnotics or the newer z-hypnotics, zopiclone and zolpidem. This paper explores possible explanations for the choice made.
METHODS: Data from the Norwegian Prescription Database covering the entire population was studied for incident users of hypnotics. Possible predictors were age, gender, previous psychotropic or analgesic drug use and prescriber speciality.
RESULTS: Of the 73,163 incident users of hypnotics, 3876 were prescribed benzodiazepine hypnotics in 2006. The strongest predictors for being prescribed benzodiazepines were previous use of anxiolytics [odds ratio (OR) 1.8, 95% confidence interval (CI) 1.7-2.0] and male gender (OR 1.5, 95% CI 1.4-1.6). Other significant predictors were antipsychotic or opioid drug use and the prescriber being a psychiatrist.
CONCLUSIONS: Z-hypnotics were commonly prescribed. Norwegian drug therapy recommendations also suggest a preference for z-hypnotics. The clear predominance of the shorter acting z-hypnotics may be due to the fact that only longer acting benzodiazepines are available in Norway. Reasons for prescribing benzodiazepines may be co-morbid psychiatric illness, such as anxiety, or a belief that benzodiazepine hypnotics are more effective than z-hypnotics.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18810397     DOI: 10.1007/s00228-008-0565-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

Review 1.  Zopiclone and zaleplon vs benzodiazepines in the treatment of insomnia: Canadian consensus statement.

Authors:  J Montplaisir; R Hawa; H Moller; C Morin; M Fortin; J Matte; L Reinish; C M Shapiro
Journal:  Hum Psychopharmacol       Date:  2003-01       Impact factor: 1.672

2.  Drugs used to treat insomnia in 2002: regulatory-based rather than evidence-based medicine.

Authors:  James K Walsh
Journal:  Sleep       Date:  2004-12-15       Impact factor: 5.849

3.  Long-term benzodiazepine use and cognitive decline in the elderly: the Epidemiology of Vascular Aging Study.

Authors:  Sabrina Paterniti; Carole Dufouil; Annick Alpérovitch
Journal:  J Clin Psychopharmacol       Date:  2002-06       Impact factor: 3.153

4.  The pre-benzodiazepine era.

Authors:  L E Hollister
Journal:  J Psychoactive Drugs       Date:  1983 Jan-Jun

Review 5.  Benzodiazepine self-administration in humans and laboratory animals--implications for problems of long-term use and abuse.

Authors:  R R Griffiths; E M Weerts
Journal:  Psychopharmacology (Berl)       Date:  1997-11       Impact factor: 4.530

Review 6.  New drugs for insomnia: comparative tolerability of zopiclone, zolpidem and zaleplon.

Authors:  Mario Giovanni Terzano; Mariano Rossi; Vincenzo Palomba; Arianna Smerieri; Liborio Parrino
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Chronic benzodiazepine administration. IV. Rapid development of tolerance and receptor downregulation associated with alprazolam administration.

Authors:  L G Miller; S Woolverton; D J Greenblatt; F Lopez; R B Roy; R I Shader
Journal:  Biochem Pharmacol       Date:  1989-11-01       Impact factor: 5.858

Review 8.  Abuse and dependence potential for the non-benzodiazepine hypnotics zolpidem and zopiclone: a review of case reports and epidemiological data.

Authors:  G Hajak; W E Müller; H U Wittchen; D Pittrow; W Kirch
Journal:  Addiction       Date:  2003-10       Impact factor: 6.526

9.  Benzodiazepine prescription practices and substance abuse in persons with severe mental illness.

Authors:  Robin E Clark; Haiyi Xie; Mary F Brunette
Journal:  J Clin Psychiatry       Date:  2004-02       Impact factor: 4.384

10.  Factors associated with high-quantity prescriptions of benzodiazepines in Sweden.

Authors:  D Isacson; K Bingefors; M Wennberg; M Dahlström
Journal:  Soc Sci Med       Date:  1993-02       Impact factor: 4.634

View more
  14 in total

1.  Use of addictive anxiolytics and hypnotics in a national cohort of incident users in Norway.

Authors:  Svein R Kjosavik; Sabine Ruths; Steinar Hunskaar
Journal:  Eur J Clin Pharmacol       Date:  2011-09-18       Impact factor: 2.953

2.  Long-term sedative use among community-dwelling adults: a population-based analysis.

Authors:  Deirdre Weymann; Emilie J Gladstone; Kate Smolina; Steven G Morgan
Journal:  CMAJ Open       Date:  2017-03-03

3.  Use of benzodiazepines and related drugs in Manitoba: a population-based study.

Authors:  Silvia Alessi-Severini; James M Bolton; Murray W Enns; Matthew Dahl; David M Collins; Dan Chateau; Jitender Sareen
Journal:  CMAJ Open       Date:  2014-10-01

4.  Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cells.

Authors:  J Jehle; E Ficker; X Wan; I Deschenes; J Kisselbach; F Wiedmann; I Staudacher; C Schmidt; P A Schweizer; R Becker; H A Katus; D Thomas
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

Review 5.  Quality analysis of research on the use of benzodiazepines by elderly patients in the emergency room: a systematic review.

Authors:  Ana Teresa R Couto; Daniel T Silva; Carina C Silvestre; Divaldo P Lyra; Lucindo J Quintans
Journal:  Eur J Clin Pharmacol       Date:  2013-02-13       Impact factor: 2.953

6.  Retrospective population cohort study on hip fracture risk associated with zolpidem medication.

Authors:  Fang-Yu Lin; Pei-Chun Chen; Chun Hui Liao; Yow-Wen Hsieh; Fung-Chang Sung
Journal:  Sleep       Date:  2014-04-01       Impact factor: 5.849

7.  [Benzodiazepine hypnotics, zolpidem and zopiclone on private prescriptions: use between 1993 and 2012].

Authors:  F Hoffmann; G Glaeske
Journal:  Nervenarzt       Date:  2014-11       Impact factor: 1.214

8.  Benefits and risks of benzodiazepines and Z-drugs: comparison of perceptions of GPs and community pharmacists in Germany.

Authors:  Falk Hoffmann
Journal:  Ger Med Sci       Date:  2013-07-18

9.  The total sale of prescription drugs with an abuse potential predicts the number of excessive users: a national prescription database study.

Authors:  Ingeborg Rossow; Jørgen G Bramness
Journal:  BMC Public Health       Date:  2015-03-25       Impact factor: 3.295

10.  Eszopiclone for insomnia.

Authors:  Susanne Rösner; Christian Englbrecht; Renate Wehrle; Göran Hajak; Michael Soyka
Journal:  Cochrane Database Syst Rev       Date:  2018-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.